{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:21:17Z","timestamp":1775154077141,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Mesothelioma is histologically divided into three subgroups: epithelioid, sarcomatoid, and biphasic types. The epithelioid or sarcomatoid type is morphologically defined by polygonal or spindle-like forms of cells, respectively. The biphasic type consists of both components. It is not yet understood how histological differentiation of mesothelioma is regulated. ERC\/mesothelin is expressed in most cases of the epithelioid type, but not in the sarcomatoid type of mesothelioma. Consequently, its expression is well correlated to the histological subtype. We hypothesized that ERC\/mesothelin expression influences the histological differentiation of mesothelioma, and tested this hypothesis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We performed studies using the overexpression or knockdown of ERC\/mesothelin in mesothelioma cells to examine its effect on cellular morphology, growth kinetics, or migration\/invasion activity, in vitro. We then transplanted ERC\/mesothelin-overexpressing and control cells into the intraperitoneal space of mice. We examined the effect of ERC\/mesothelin overexpression on mouse survival and tumor phenotype.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In vitro cell culture manipulations of ERC\/mesothelin expression did not affect cellular morphology or proliferation, although its overexpression enhanced cellular adhesion and the migration\/invasion activity of mesothelioma cells. The survival rate of mice following intraperitoneal transplantation of ERC\/mesothelin-overexpressing mesothelioma cells was significantly lower than that of mice with control cells. The histological evaluation of the tumors, however, did not show any morphological difference between two groups, and our hypothesis was not validated. Unexpectedly, both groups (ERC\/mesothelin-overexpressing and control) of mesothelioma cells that were morphologically monophasic and spindle-like in vitro differentiated into a biphasic type consisting of polygonal and spindle-like components in the transplanted tumor, irrespective of ERC\/mesothelin expression.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>These results suggested that the histological transition of mesothelioma between epithelioid and sarcomatoid types may be reversible and regulated not by ERC\/mesothelin, but by other unknown mechanisms.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12931-020-01449-2","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T10:03:28Z","timestamp":1594893808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC\/mesothelin expression"],"prefix":"10.1186","volume":"21","author":[{"given":"Masataka","family":"Kojima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8143-5764","authenticated-orcid":false,"given":"Kazunori","family":"Kajino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Momose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadila","family":"Wali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May Thinzar","family":"Hlaing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhisa","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Okio","family":"Hino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"1449_CR1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/BF01197777","volume":"121","author":"O Hino","year":"1995","unstructured":"Hino O, Kobayashi E, Nishizawa M, Kubo Y, Kobayashi T, Hirayama Y, et al. Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol. 1995;121:602\u20135.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1449_CR2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1006\/bbrc.2000.3280","volume":"275","author":"Y Yamashita","year":"2000","unstructured":"Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun. 2000;275:134\u201340.","journal-title":"Biochem Biophys Res Commun"},{"key":"1449_CR3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","volume":"93","author":"K Chang","year":"1996","unstructured":"Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93:136\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1449_CR4","doi-asserted-by":"crossref","first-page":"21984","DOI":"10.1074\/jbc.270.37.21984","volume":"270","author":"T Kojima","year":"1995","unstructured":"Kojima T, Oh-Eda M, Hattori K, Taniguchi Y, Tamura M, Ochi N, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem. 1995;270:21984\u201390.","journal-title":"J Biol Chem"},{"key":"1449_CR5","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1073\/pnas.96.20.11531","volume":"96","author":"N Scholler","year":"1999","unstructured":"Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, et al. Soluble member(s) of the mesothelin\/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A. 1999;96:11531\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1449_CR6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0046-8177(03)00177-1","volume":"34","author":"HF Frierson Jr","year":"2003","unstructured":"Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003;34:605\u20139.","journal-title":"Hum Pathol"},{"key":"1449_CR7","first-page":"67","volume":"24","author":"D Cao","year":"2004","unstructured":"Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol. 2004;24:67\u201372.","journal-title":"Int J Gynecol Pathol"},{"key":"1449_CR8","first-page":"6281","volume":"60","author":"CD Hough","year":"2000","unstructured":"Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, et al. Large-scale serial anarysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000;60:6281\u20137.","journal-title":"Cancer Res"},{"key":"1449_CR9","first-page":"3862","volume":"7","author":"P Argani","year":"2001","unstructured":"Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862\u20138.","journal-title":"Clin Cancer Res"},{"key":"1449_CR10","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","volume":"279","author":"A Rump","year":"2004","unstructured":"Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279:9190\u20138.","journal-title":"J Biol Chem"},{"key":"1449_CR11","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/srep01870","volume":"3","author":"S-H Chen","year":"2013","unstructured":"Chen S-H, Hung W-C, Wang P, Paul C, Konstantopoulos K. Mesothelin binding of CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep. 2013;3:1870. https:\/\/doi.org\/10.1038\/srep01870.","journal-title":"Sci Rep"},{"key":"1449_CR12","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","volume":"18","author":"EL Servais","year":"2012","unstructured":"Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res. 2012;18:2478\u201389.","journal-title":"Clin Cancer Res"},{"key":"1449_CR13","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-08-0095","volume":"6","author":"U Bharadwaj","year":"2008","unstructured":"Bharadwaj U, Li M, Chen C, Yao Q. Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3. Mol Cancer Res. 2008;6:1755\u201365.","journal-title":"Mol Cancer Res"},{"key":"1449_CR14","first-page":"2219","volume":"20","author":"D-D Yin","year":"2014","unstructured":"Yin D-D, You L-H, Yuan Q-X, Liang X-D, Wang N, Wang L-T, et al. Mesothelin promotes cell proliferation in the remodeling of neonatal rat pancreas. World J Gastroenterol. 2014;20:2219\u201340.","journal-title":"World J Gastroenterol"},{"key":"1449_CR15","doi-asserted-by":"crossref","first-page":"e33214","DOI":"10.1371\/journal.pone.0033214","volume":"7","author":"K Wang","year":"2012","unstructured":"Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor Y, Meyer A, et al. Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS ONE. 2012;7:e33214.","journal-title":"PLoS ONE"},{"key":"1449_CR16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12199-007-0017-6","volume":"13","author":"K Inai","year":"2008","unstructured":"Inai K. Pathology of mesothelioma. Environ Health Prev Med. 2008;13:60\u20134.","journal-title":"Environ Health Prev Med"},{"key":"1449_CR17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475\u201388.","journal-title":"Nat Rev Cancer"},{"key":"1449_CR18","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","volume":"5","author":"MT Milano","year":"2010","unstructured":"Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol. 2010;5:1841\u20138.","journal-title":"J Thorac Oncol"},{"key":"1449_CR19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","volume":"196","author":"RR Meyerhoff","year":"2015","unstructured":"Meyerhoff RR, Yang C-FJ, Speicher PJ, Gulack BC, Hartwig MG, D'Amico TA, et al. Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database. J Surg Res. 2015;196:23\u201332.","journal-title":"J Surg Res"},{"key":"1449_CR20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","volume":"16","author":"NG Ordonez","year":"2003","unstructured":"Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003;16:192\u20137.","journal-title":"Mod Pathol"},{"key":"1449_CR21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1827.2007.02080.x","volume":"57","author":"K Kushitani","year":"2007","unstructured":"Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung carcinoma. Pathol Int. 2007;57:190\u20139.","journal-title":"Pathol Int"},{"key":"1449_CR22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000478-200302000-00002","volume":"27","author":"M Miettinen","year":"2003","unstructured":"Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003;27:150\u20138.","journal-title":"Am J Surg Pathol"},{"key":"1449_CR23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1349-7006.2006.00184.x","volume":"97","author":"N Usami","year":"2006","unstructured":"Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama Y, Mori S, et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006;97:387\u201394.","journal-title":"Cancer Sci"},{"key":"1449_CR24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1440-1827.2009.02344.x","volume":"59","author":"K Ishikawa","year":"2009","unstructured":"Ishikawa K, Segawa T, Hagiwara Y, Maeda M, Abe M, Hino O. Establishment of novel mAb to human ERC\/mesothelin useful for study and diagnosis of ERC\/mesothelin-expressing cancers. Pathol Int. 2009;59:161\u20136.","journal-title":"Pathol Int"},{"key":"1449_CR25","first-page":"156","volume-title":"WHO classification of tumours of the lung, pleura, thymus and heart","author":"F Galateau-Salle","year":"2015","unstructured":"Galateau-Salle F, Dacic S, Ordonez NG, Churg A, Hammar S, Rice DC, et al. Epithelioid mesothelioma. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, editors. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: International Agency for Research on Cancer; 2015. p. 156\u201364.","edition":"4"},{"key":"1449_CR26","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/ajcp\/110.3.397","volume":"110","author":"DW Henderson","year":"1998","unstructured":"Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ. Am J Clin Pathol. 1998;110:397\u2013404.","journal-title":"Am J Clin Pathol"},{"key":"1449_CR27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00000478-198601000-00005","volume":"10","author":"JW Bolen","year":"1986","unstructured":"Bolen JW, Hammar SP, McNutt MA. Reactive and neoplastic serosal tissue. A light-microscopic, ultrastructural and immunocytochemical study. Am J Surg Pathol. 1986;10:34\u201347.","journal-title":"Am J Surg Pathol"},{"key":"1449_CR28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/01913128709048326","volume":"11","author":"JW Bolen","year":"1987","unstructured":"Bolen JW, Hammar SP, McNutt MA. Serosal tissue: reactive tissue as a model for understanding mesothelioma. Ultrastruct Pathol. 1987;11:251\u201362.","journal-title":"Ultrastruct Pathol"},{"key":"1449_CR29","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/modpathol.2016.89","volume":"29","author":"SBSP Terra","year":"2016","unstructured":"Terra SBSP, Jang JS, Bi L, Kipp BR, Jen J, Yi ES, et al. Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases. Mod Pathol. 2016;29:824\u201331.","journal-title":"Mod Pathol"},{"key":"1449_CR30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15586\/jkcvhl.2017.70","volume":"4","author":"S Wei","year":"2017","unstructured":"Wei S, Al-Saleem T. The pathology and molecular genetics of sarcomatoid renal cell carcinoma: a mini-review. J Kidney Cancer VHL. 2017;4:19\u201323.","journal-title":"J Kidney Cancer VHL"},{"key":"1449_CR31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1477-7819-11-252","volume":"11","author":"S-Y Huang","year":"2013","unstructured":"Huang S-Y, Shen S-J, Li X-Y. Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases. World J Surg Oncol. 2013;11:252.","journal-title":"World J Surg Oncol"},{"key":"1449_CR32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3892\/mco.2014.411","volume":"3","author":"H Ozturk","year":"2015","unstructured":"Ozturk H. Multiple carcinosarcomas of the kidney: a case report and review of the literature. Mol Clin Oncol. 2015;3:212\u20136.","journal-title":"Mol Clin Oncol"},{"key":"1449_CR33","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.18632\/oncotarget.3765","volume":"6","author":"JJ Sacco","year":"2015","unstructured":"Sacco JJ, Kenyani J, Butt Z, Carter R, Chew HY, Cheeseman LP, et al. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors. Oncotarget. 2015;6:13757\u201371.","journal-title":"Oncotarget."},{"key":"1449_CR34","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2353\/ajpath.2009.080721","volume":"174","author":"S Romagnoli","year":"2009","unstructured":"Romagnoli S, Fasoli E, Vaira V, Falleni M, Pellegrini C, Catania A, et al. Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. Am J Pathol. 2009;174:762\u201370.","journal-title":"Am J Pathol"},{"key":"1449_CR35","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4161\/cc.27546","volume":"13","author":"D Di Marzo","year":"2014","unstructured":"Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, et al. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle. 2014;13:652\u201365.","journal-title":"Cell Cycle"},{"key":"1449_CR36","first-page":"1227","volume":"55","author":"Y Sekido","year":"1995","unstructured":"Sekido Y, Pass HI, Bader S, Mew DJY, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55:1227\u201331.","journal-title":"Cancer Res"},{"key":"1449_CR37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000356874","volume":"86","author":"T Iwanami","year":"2014","unstructured":"Iwanami T, Uramoto H, Nakagawa M, Shimokawa H, Yamada S, Kohno K, et al. Clinical significance of epithelial-mesenchymal transition-associated markers in malignant pleural mesothelioma. Oncology. 2014;86:109\u201316.","journal-title":"Oncology"},{"key":"1449_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0463.2012.02931.x","volume":"121","author":"H Merikallio","year":"2013","unstructured":"Merikallio H, Paakko P, Salmenkivi K, Kinnula V, Harju T, Soini Y. Expression of snail, twist, and Zeb1 in malignant mesothelioma. APMIS. 2013;121:1\u201310.","journal-title":"APMIS."},{"key":"1449_CR39","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/ncb2610","volume":"14","author":"Y Rinkevich","year":"2012","unstructured":"Rinkevich Y, Mori T, Sahoo D, Xu P-X, Bermingham JR, Weissman IL. Identification and prospective isolation of a mesothelial precursor lineage giving rise to smooth muscle cells & fibroblasts for mammalian internal organs, and their vasculature. Nat Cell Biol. 2012;14:1251\u201360.","journal-title":"Nat Cell Biol"},{"key":"1449_CR40","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1016\/j.celrep.2019.02.016","volume":"26","author":"T Colunga","year":"2019","unstructured":"Colunga T, Hayworth M, Kre\u03b2 S, Reynolds DM, Chen L, Nazor KL, et al. Human pluripotent stem cell-derived multipotent vascular progenitors of the mesothelium lineage have utility in tissue engineering and repair. Cell Rep. 2019;26:2566\u201379.","journal-title":"Cell Rep"},{"key":"1449_CR41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1242\/jcs.058669","volume":"123","author":"M Morimoto","year":"2010","unstructured":"Morimoto M, Liu Z, Cheng H-T, Winters N, Bader D, Kopan R. Canonical notch signaling in the developing lung is required for determination of arterial smooth muscle cells and selection of Clara versus ciliated cell fate. J Cell Sci. 2010;123:213\u201324.","journal-title":"J Cell Sci"},{"key":"1449_CR42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1365-2559.2003.01583.x","volume":"42","author":"DR Lucas","year":"2003","unstructured":"Lucas DR, Pass HI, Madan SK, Adsay NV, Wali A, Tabaczka P, et al. Sarcomatoid mesothelioma and its hitological mimics: a comparative immunohistochemical study. Histopathol. 2003;42:270\u20139.","journal-title":"Histopathol."},{"key":"1449_CR43","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/modpathol.2009.180","volume":"23","author":"S Klebe","year":"2010","unstructured":"Klebe S, Brownlee NA, Mahar A, Burchette JL, Sporn TA, Vollmer RT, et al. Sarcomatoid mesothelioma: a clinical-pathologic correlation of 326 cases. Mod Pathol. 2010;23:470\u20139.","journal-title":"Mod Pathol"},{"key":"1449_CR44","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","volume":"66","author":"F Lopez-Rios","year":"2006","unstructured":"Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K, et al. Global gene expression profiling of pleural mesotheliomas: overexpression of Aurora kinases and p16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res. 2006;66:2970\u20139.","journal-title":"Cancer Res"},{"key":"1449_CR45","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-12-2117","volume":"19","author":"A De Rienzo","year":"2013","unstructured":"De Rienzo A, Richards WG, Yeap BY, Coleman MH, Sugarbaker PE, Chirieac LR, et al. Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma. Clin Cancer Res. 2013;19:2493\u2013502.","journal-title":"Clin Cancer Res"},{"key":"1449_CR46","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1046\/j.1365-2559.1997.d01-604.x","volume":"30","author":"S Matsukuma","year":"1997","unstructured":"Matsukuma S, Suda K, Abe H, Ogata S, Wada R. Metastatic cancer involving pancreatic duct epithelium and its mimicry of primary pancreatic cancer. Histopathology. 1997;30:208\u201313.","journal-title":"Histopathology"},{"key":"1449_CR47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/path.1711600203","volume":"160","author":"NA Shepherd","year":"1990","unstructured":"Shepherd NA, Hall PA. Epithelial-mesenchymal interactions can influence the phenotype of carcinoma metastases in the mucosa of the intestine. J Pathol. 1990;160:103\u20139.","journal-title":"J Pathol"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01449-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-020-01449-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01449-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T23:55:42Z","timestamp":1626393342000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-020-01449-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1449"],"URL":"https:\/\/doi.org\/10.1186\/s12931-020-01449-2","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"assertion":[{"value":"29 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments in this study were approved by the Institute Animal Care and Use Committee of Juntendo University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}